Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States

BACKGROUND: Combination axitinib plus pembrolizumab is a standard of care in the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC). This analysis describes the clinical characteristics, treatment management and outcomes of patients receiving first-line (1L) axitini...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakharia, Yousef, Thomaidou, Despina, Li, Benjamin, Siu, Gordon, Levin, Rebecca, Vlahiotis, Anna, Rao, Dharanija, Zanotti, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161634/
https://www.ncbi.nlm.nih.gov/pubmed/35664758
http://dx.doi.org/10.3389/fonc.2022.861189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161634/
https://www.ncbi.nlm.nih.gov/pubmed/35664758
http://dx.doi.org/10.3389/fonc.2022.861189

Ejemplares similares